EGFR and non-small cell lung carcinoma: Although, our previous study (23) attempted to investigate the performance of PFS prediction using interim PET/CT (∆SUVmax and ∆SUVmean) in stage IIIC/IV EGFR-mutant NSCLC patients with EGFR-TKI therapy, this is a single-centre study with a small cohort size (78 patients), the AUCs of the ∆SUVmax and ∆SUVmean were 0.764 and 0.725, respectively.